New Drugs 2008-2009- Pharmacist


  Credits  2

This product is currently out of stock and unavailable.

In 2008, the FDA approved 21 new molecular entities (NMEs) and 7 significant new biologicals, compared with 17 NMEs and 2 biologic products in 2007. Despite the increase in approvals, there are no apparent blockbuster drugs. While the pharmaceutical industry suggests that “newly approved” means “new and improved,” this is often far from the truth. Many recently approved drugs are not innovations, but rather “me-too” products. In addition to misleading marketing, the true value of new drugs is often obscured by the incomplete and potentially biased state of the published literature. Incomplete post-marketing studies that are requested by the FDA at the time of approval also cloud the real benefits or disadvantages of new drugs. With all these influences, it is essential that providers use a critical eye when sifting through the available information, in order to better educate patients and colleagues. New is not always better. This issue reviews 8 new drugs or novel new formulations that you are most likely to encounter in clinical practice including alvimopan (Entereg®), certolizumab (Cimzia®), desvenlafaxine (Pristiq®), fenofibric acid (TriLipix®), fesoerodine (Toviaz®), methylnaltrexone (Relistor®), milnacipran (Savella®), and silodosin (Rapaflo®). The reviews consist of the indication, the drug’s role in therapy, usual dose, precautions, drug interactions, and practical patient counseling points. Handy tables encompass brief overviews for 11 additional new drugs, new formulations you are likely to see in practice, and new combination products.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-09-004-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.